Green Cross Corp
KRX:006280
Green Cross Corp
Treasury Stock
Green Cross Corp
Treasury Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Treasury Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Green Cross Corp
KRX:006280
|
Treasury Stock
-â‚©35.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
||
Celltrion Inc
KRX:068270
|
Treasury Stock
-â‚©2.2T
|
CAGR 3-Years
-114%
|
CAGR 5-Years
-66%
|
CAGR 10-Years
N/A
|
||
SK Bioscience Co Ltd
KRX:302440
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
H
|
Hugel Inc
KOSDAQ:145020
|
Treasury Stock
-â‚©262.9B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Treasury Stock
-â‚©4.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
KOSDAQ:196170
|
Treasury Stock
-â‚©1.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Green Cross Corp
Glance View
Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.
See Also
What is Green Cross Corp's Treasury Stock?
Treasury Stock
-35.7B
KRW
Based on the financial report for Sep 30, 2024, Green Cross Corp's Treasury Stock amounts to -35.7B KRW.
What is Green Cross Corp's Treasury Stock growth rate?
Treasury Stock CAGR 5Y
0%
Over the last year, the Treasury Stock growth was 0%.